Based on the measurements of operating efficiency obtained from Medtronic PLC's historical financial statements, Medtronic PLC may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Medtronic PLC's Cash is comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 71.4 B in 2024, whereas Short Term Debt is likely to drop slightly above 1.2 B in 2024. Key indicators impacting Medtronic PLC's financial strength include:
The financial analysis of Medtronic PLC is a critical element in measuring its lifeblood. Investors should not minimize Medtronic PLC's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Cash And Equivalents
1.32 Billion
Medtronic
Select Account or Indicator
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Stock Based Compensation
Change To Liabilities
Other Cashflows From Investing Activities
Change To Account Receivables
Total Cashflows From Investing Activities
Change To Operating Activities
Investments
Net Borrowings
Change To Netincome
Change Receivables
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Accounts Payable
Other Liab
Other Assets
Long Term Debt
Good Will
Short Term Investments
Accumulated Other Comprehensive Income
Common Stock
Property Plant Equipment
Common Stock Total Equity
Property Plant And Equipment Gross
Current Deferred Revenue
Long Term Investments
Short Long Term Debt
Net Tangible Assets
Deferred Long Term Liab
Noncontrolling Interest In Consolidated Entity
Retained Earnings Total Equity
Long Term Debt Total
Non Current Liabilities Other
Capital Surpluse
Capital Lease Obligations
Net Invested Capital
Cash And Equivalents
Net Working Capital
Depreciation And Amortization
Interest Expense
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Selling General Administrative
Net Income Applicable To Common Shares
Net Income From Continuing Ops
Non Recurring
Minority Interest
Tax Provision
Non Operating Income Net Other
Interest Income
Extraordinary Items
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Medtronic PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Medtronic PLC's financial statements are interrelated, with each one affecting the others. For example, an increase in Medtronic PLC's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Medtronic PLC's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medtronic PLC. Check Medtronic PLC's Beneish M Score to see the likelihood of Medtronic PLC's management manipulating its earnings.
Medtronic PLC Stock Summary
Medtronic PLC competes with Edwards Lifesciences, Abbott Laboratories, Boston Scientific, Zimmer Biomet, and Stryker. Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company was founded in 1949 and is headquartered in Dublin, Ireland. Medtronic operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 95000 people.
The reason investors look at the income statement is to determine what Medtronic PLC's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Medtronic PLC's current stock value. Our valuation model uses many indicators to compare Medtronic PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medtronic PLC competition to find correlations between indicators driving Medtronic PLC's intrinsic value. More Info.
Medtronic PLC is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.56 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Medtronic PLC is roughly 1.80 . At this time, Medtronic PLC's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Medtronic PLC by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Medtronic PLC Systematic Risk
Medtronic PLC's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medtronic PLC volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Medtronic PLC correlated with the market. If Beta is less than 0 Medtronic PLC generally moves in the opposite direction as compared to the market. If Medtronic PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medtronic PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medtronic PLC is generally in the same direction as the market. If Beta > 1 Medtronic PLC moves generally in the same direction as, but more than the movement of the benchmark.
Medtronic PLC Thematic Clasifications
Medtronic PLC is part of several thematic ideas from Dividend Beast to Obamacare Repeal. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Medtronic PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Medtronic PLC's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Medtronic PLC growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Medtronic PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medtronic PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medtronic PLC based on widely used predictive technical indicators. In general, we focus on analyzing Medtronic Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medtronic PLC's daily price indicators and compare them against related drivers.
When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.